Ashwagandha(Sutter Fairfield Surgery Center)

Arjuna Natural showcases its ashwagandha ingredient crafted to maintain brain function in mature adults KOCHI, India, April 23, 2025 /PRNewswire/ -- A new clinical study of Somin-On™, an ashwagandha (Withania somnifera) withanolide extract standardized to Sominone, highlights its potential for improving memory and cognitive function in adults with mild cognitive impairment (MCI). Arjuna Natural will showcase Somin-On at Vitafoods Europe, Barcelona, 20-22nd May 2025, Booth 4J2. Continue Reading Somin-On™ Ashwagandha Improves Memory in Adults with Mild Cognitive Impairment Somin-on is the newest addition to Arjuna Natural, Pvt. Ltd.'s prized portfolio of branded botanical formulations. Unique to this ashwagandha formulation is that it is standardized to a 2% content Sominone (established via HPLC) and is designed to focus primarily on enhancing specific cognitive functions, such as attention and memory retention. Plant-powered cognitive support "Our new ashwagandha formulation was developed in direct response to the rising concerns of cognitive decline among today's aging population," exclaims Benny Antony, PhD, Joint Managing Director of Arjuna Natural. "This group is actively seeking natural solutions to maintain mental clarity and focus, and help prevent any potential onset of dementia as its members age. Somin-On offers a promising, safe and natural approach for supporting brain function helping older adults stay sharp and mentally agile." MCI is a condition where individuals experience noticeable memory and cognition difficulties, although not yet severe enough to interfere with daily life. Globally, some 16% of people older than 70 years experience some type of MCI. However, research has shown that approximately 50% of people diagnosed with MCI will develop Alzheimer's disease within 5 years. MCI is also considered an early indicator of other forms of dementia. "There currently is no approved standard of treatment available for MCI in the allopathic medical world," informs Antony. "Somin-On is our answer to this unmet need and to help address the issue of cognitive decline using natural agents." Led by Hari Prakash Rai, PhD, this randomized, double-blind, placebo-controlled trial was published in the Journal of Psychopharmacology in March 2025 and enrolled 40 adults with MCI. Conducted at the Hi-Tech Hospital and Trauma Center, Jhansi, Uttar Pradesh, India, the participants were divided into two groups: one received 250mg of Somin-On daily, while the other received a placebo over a period of 60 days, with assessments conducted at 30 and 60 days. Fuel for focus The study subjects taking Somin-On showed significant improvements in multiple areas of cognitive function compared to the placebo. Improvements were observed in immediate memory, general memory, and working memory, as assessed by the Wechsler Memory Scale-III (WMS-III). Somin-On clearly outperformed the placebo in other mental parameters. Visuospatial processing was improved significantly between day 30 and 60 in the Somin-On group according to scores of the Shepard Mental Rotation Test. Moreover, Somin-On supplementation was associated with significant improvement in additional memory assessments including the Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) which examines various memory functions, including repeating lists of words, arithmetic, language use and comprehension as well as basic motor skills. The results suggest a potential role for Somin-On in enhancing attention, accelerating information processing, and improving overall cognitive performance, while reducing cognitive impairment. "Sominone, derived from Withania somnifera, is identified as the main active metabolite responsible for these specific effects," explains Antony. "Ashwagandha is a traditional Ayurvedic herb that has been widely used for centuries to manage stress and anxiety, and cognitive support function. This compound has been identified and extensively analyzed for its potential benefits in enhancing memory and cognitive functions." Sominone has been shown to repair nerve cells and neural connections in rat brain cells damaged by amyloid-beta, a plaque forming protein known to damage brains cells when it builds up in the brain. In animal models, it has been shown to enhance neurite outgrowth, and improve spatial memory as well as nerve cell growth and repair leading to cognitive enhancement. Moreover, the ashwagandha extract is known to reduce oxidative stress and mitochondrial dysfunction, contributing to its neuroprotective and anti-degenerative properties. Somin-On was crafted as a sequel to Arjuna's flagship ashwagandha extract, Shoden. Standardized to 35% withanolide glycosides, Shoden is designed to alleviate stress and anxiety, and improve sleep quality, and is supported by multiple clinical studies. About Arjuna Natural For more than a quarter of a century Arjuna Natural has been India's leading manufacturer of standardized spice and botanical extracts for food supplement industries. Established in 1989, the company is, dedicated to eco-friendly and sustainable practices and has grown rapidly, serving customers in 70 countries. Arjuna has an advanced research facility that works in collaboration with international universities on phytochemistry, pharmacokinetics, formulation, development, and pre-clinical and toxicity research. Arjuna Natural's facilities comply with the highest world standards, are GMP-certified, and have ISO, NSF, Star-K kosher, and halal certification. For further information, please contact: Company contact Arjuna Natural Pvt. Ltd. Benny Antony, PhD Joint Managing Director Email: [email protected] Website: Twitter: @ArjunaExtracts Press Contact NutriPR Liat Simha Tel: +972-9-9742893 E-mail: [email protected] Website: Photo: SOURCE Arjuna Natural Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has published a pioneering study that reexamines the role of amyloid β-peptides (Aβ) in Alzheimer's disease (AD). This research, featured in Frontiers in Neuroscience, proposes a paradigm shift in understanding the function of Aβ, suggesting they may serve a protective role against metal toxicity in the brain rather than being primary culprits in AD progression.​ A Protective Perspective on Amyloid β-Peptides Alzheimer's disease has long been associated with the accumulation of amyloid plaques, leading to the prevailing belief that Aβ contributes directly to neurodegeneration. Cavaleri's study challenges this notion by presenting evidence that Aβ and the enzyme β-secretase (BACE1) are integral to a cellular defense mechanism aimed at sequestering harmful metal ions. This chelation process may prevent oxidative stress and neuronal damage by neutralizing metal-induced toxicity. It is only when this protective system becomes overwhelmed by excessive metal exposure that neurodegenerative symptoms emerge. Implications for Alzheimer's Research and Treatment This groundbreaking perspective opens new avenues for Alzheimer's research, emphasizing the need to explore environmental factors, such as metal exposure, in disease development. By shifting the focus from solely targeting Aβ for therapeutic intervention to understanding its protective functions, scientists can develop more effective strategies that address the root causes of neurodegeneration.​ Franco Cavaleri: A Leader in Biomedical Innovation Franco Cavaleri's extensive background in nutritional biochemistry and natural medicine pharmacology has positioned him at the forefront of biomedical research. As CEO and Research Director of Biologic Pharmamedical Research and Manufacturing, Cavaleri has dedicated his career to bridging the gap between natural health products and pharmaceutical science. His work has led to significant advancements in understanding inflammation, neurodegenerative diseases, and the pharmacology of natural compounds. ​ Beyond his groundbreaking research, Franco Cavaleri is the best-selling author and host of the Potential Within podcast, and a former IFBB Mr. North America Bodybuilding Champion. His powerful personal story—overcoming severe ulcerative colitis without surgery through targeted natural medicine and science-backed supplementation—fuels his mission to transform modern health care. Through innovations like his patented Curcumin BioBDMC30™, Ashwith™ Ashwagandha, Keto BHB-BA™, and Glyvia™ sweetener (among over 15 other patents), Cavaleri is redefining what proactive health looks like. His integrative approach fuses rigorous biomedical science with holistic lifestyle and nutraceutical interventions, offering a sustainable solution to an overburdened healthcare system. By empowering individuals to take control of their health through nutrition, precision supplementation, and evidence-based self-care, Cavaleri’s work aims not only to reduce dependency on conventional medicine—but to enable longer, healthier, and more vibrant lives. About Biologic Pharmamedical Research and Manufacturing Biologic Pharmamedical Research and Manufacturing, based in Vancouver, Canada with manufacturing facilities in both Canada and the USA, specializes in the research and development of evidence-based nutraceuticals and pharmaceuticals. Under Cavaleri's leadership, the company focuses on innovative solutions that merge natural medicine with modern pharmacological principles to address complex health challenges as well as prevention. ​BiologicPharmaMedical Access the Full Study For a comprehensive understanding of this transformative research, the full study is available at Frontiers in Neurology. Media Contact Christina WeizmannCommunications LeadPhone: 604.684.9321Email: christina.w@biologic-med.com Business Development Contact Mike SchmidtVP Business & Product DevelopmentPhone: 1.855.518.8858Email: info@biologicpharmamedical.com